Caris Life Sciences is a next-generation AI TechBio company and precision medicine pioneer that provides comprehensive molecular profiling through Whole Exome and Whole Transcriptome Sequencing. The company launched MI Cancer Seek after receiving FDA approval; it is the first and only simultaneous WES/WTS-based assay with FDA-approved CDx indications for molecular profiling of solid tumors in adult and pediatric patients. In 2024 Caris commercially launched Caris Assure, a minimally invasive, blood-based assay using a circulating Nucleic Acid Sequencing (cNAS) approach to analyze cell-free DNA and RNA as well as genomic DNA and mRNA from white blood cells to distinguish somatic tumor, incidental clonal hematopoiesis and incidental germline variants. Caris combines sequencing power, big data and AI/machine learning to build a large-scale, multimodal database and computing capability to analyze the molecular complexity of disease. The company says it will use its platform to deliver next-generation precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development and to bring its science and technologies to more patients. Financially, Caris closed a $168 million growth capital round and has raised $1.86 billion in capital since 2018. Caris Life Sciences develops comprehensive molecular profiling that analyzes DNA (whole exome sequencing), RNA (whole transcriptome sequencing), and protein biomarkers to reveal a patient’s molecular blueprint for selecting therapies. The company applies sophisticated AI and machine learning to identify proprietary signatures that classify cancer at the molecular level and predict patient response. Caris maintains a molecular database of over 455,000 tumor profiles, including more than 350,000 profiles with matched molecular data and clinical outcomes. Founded in 2008, the company positions itself as a leading innovator in precision medicine. Caris plans to use new capital to repay outstanding debt, enhance its precision medicine platform, and for general corporate purposes. Since 2018 the company has raised approximately $1.7 billion in capital. Caris Life Sciences provides molecular profiling services that assess DNA, RNA and proteins to create a molecular blueprint that supports personalized cancer treatment decisions. The company combines its service offering, Caris Molecular Intelligence®, with its proprietary AI analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. Caris couples these molecular data with mature clinical outcomes on thousands of patients to generate insights for patients, physicians, payers and biopharmaceutical organizations. The company is headquartered in Irving, Texas and has offices in Phoenix, Denver, New York and Basel, Switzerland, providing services across the U.S., Europe, Asia and other international markets. David D. Halbert leads the company as Chairman and CEO. The business emphasizes integrating molecular science and artificial intelligence to advance precision medicine. Caris Life Sciences develops molecular profiling and analytics to guide precision oncology decisions, offering whole exome and whole transcriptome sequencing and proteome analysis. Its product suite includes MI Exome™ and MI Transcriptome™ sequencing, Caris MAI™ (Molecular Artificial Intelligence) and the DEAN™ analytics engine. Caris Pharmatech provides Just-In-Time clinical trial solutions and a network of over 200 research-ready oncology sites to speed site activation and patient enrollment. Headquartered in Irving, Texas, the company also has offices in Phoenix, Denver, New York and Basel and serves markets in the U.S., Europe, Asia and other international regions. The company will use new capital to fund continued growth in precision medicine, accelerate product development and pursue initiatives in the clinical trial and biopharmaceutical markets. Caris is led by Chairman and CEO David D. Halbert. Caris Life Sciences is an Irving, Texas-based provider of molecular science focused on precision medicine through molecular profiling of DNA, RNA and proteins. The company advances a suite of offerings including Caris Molecular Intelligence®, the ADAPT Biotargeting System™, and the DEAN™ AI analytics engine that together support its Next Generation Profiling™. Next Generation Profiling™ aims to analyze the whole exome, whole transcriptome and complete cancer proteome and couple that molecular data with mature clinical outcomes to deliver more precise treatment recommendations. Caris offers services throughout the U.S., Europe, Asia and other international markets. Led by Chairman and CEO David D. Halbert, the company plans to continue development of Next Generation Profiling™ and expand commercial, clinical and R&D laboratory capacity. In January 2018 it raised $150M in funding provided as senior secured debt and convertible notes to support development and other strategic initiatives.

Total raised

$1.9B

Funding rounds

7

Latest round

Equity

Latest activity

Apr 2025